nodes	percent_of_prediction	percent_of_DWPC	metapath
Dextroamphetamine—Dysmenorrhoea—Mesalazine—Crohn's disease	0.0131	0.0283	CcSEcCtD
Dextroamphetamine—Amphetamine—SLC22A5—Crohn's disease	0.0102	0.33	CrCbGaD
Dextroamphetamine—Methamphetamine—SLC22A5—Crohn's disease	0.00943	0.305	CrCbGaD
Dextroamphetamine—Libido decreased—Mesalazine—Crohn's disease	0.0093	0.0202	CcSEcCtD
Dextroamphetamine—Disturbance in sexual arousal—Mesalazine—Crohn's disease	0.00856	0.0185	CcSEcCtD
Dextroamphetamine—Toxic epidermal necrolysis—Azathioprine—Crohn's disease	0.00853	0.0185	CcSEcCtD
Dextroamphetamine—Affect lability—Mesalazine—Crohn's disease	0.00849	0.0184	CcSEcCtD
Dextroamphetamine—Pseudoephedrine—TNF—Crohn's disease	0.00822	0.266	CrCbGaD
Dextroamphetamine—Mood swings—Mesalazine—Crohn's disease	0.00817	0.0177	CcSEcCtD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—GPR65—Crohn's disease	0.00801	0.0158	CbGpPWpGaD
Dextroamphetamine—Abdominal pain upper—Mesalazine—Crohn's disease	0.00788	0.0171	CcSEcCtD
Dextroamphetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A1—Crohn's disease	0.00748	0.0147	CbGpPWpGaD
Dextroamphetamine—Anorexia—Mercaptopurine—Crohn's disease	0.00745	0.0161	CcSEcCtD
Dextroamphetamine—Stevens-Johnson syndrome—Azathioprine—Crohn's disease	0.00723	0.0157	CcSEcCtD
Dextroamphetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A4—Crohn's disease	0.00716	0.0141	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A5—Crohn's disease	0.00716	0.0141	CbGpPWpGaD
Dextroamphetamine—Viral infection—Prednisone—Crohn's disease	0.00696	0.0151	CcSEcCtD
Dextroamphetamine—Photosensitivity reaction—Mesalazine—Crohn's disease	0.0068	0.0147	CcSEcCtD
Dextroamphetamine—Decreased appetite—Mercaptopurine—Crohn's disease	0.00679	0.0147	CcSEcCtD
Dextroamphetamine—Weight decreased—Mesalazine—Crohn's disease	0.00674	0.0146	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.00674	0.0146	CcSEcCtD
Dextroamphetamine—Depression—Mesalazine—Crohn's disease	0.00663	0.0144	CcSEcCtD
Dextroamphetamine—Stevens-Johnson syndrome—Mesalazine—Crohn's disease	0.00659	0.0143	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR ligand binding—CCR9—Crohn's disease	0.00656	0.0129	CbGpPWpGaD
Dextroamphetamine—Urinary tract infection—Mesalazine—Crohn's disease	0.00646	0.014	CcSEcCtD
Dextroamphetamine—Sweating—Mesalazine—Crohn's disease	0.00637	0.0138	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Azathioprine—Crohn's disease	0.00619	0.0134	CcSEcCtD
Dextroamphetamine—Body temperature increased—Mercaptopurine—Crohn's disease	0.00617	0.0134	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR ligand binding—GPR65—Crohn's disease	0.0061	0.012	CbGpPWpGaD
Dextroamphetamine—Hypersensitivity—Mercaptopurine—Crohn's disease	0.00576	0.0125	CcSEcCtD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CCR6—Crohn's disease	0.0057	0.0112	CbGpPWpGaD
Dextroamphetamine—Erythema multiforme—Mesalazine—Crohn's disease	0.00564	0.0122	CcSEcCtD
Dextroamphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC22A4—Crohn's disease	0.00546	0.0108	CbGpPWpGaD
Dextroamphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC22A5—Crohn's disease	0.00546	0.0108	CbGpPWpGaD
Dextroamphetamine—Euphoric mood—Prednisone—Crohn's disease	0.0054	0.0117	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR downstream signaling—MLN—Crohn's disease	0.00535	0.0105	CbGpPWpGaD
Dextroamphetamine—Diarrhoea—Mercaptopurine—Crohn's disease	0.00534	0.0116	CcSEcCtD
Dextroamphetamine—TAAR1—Signaling by GPCR—ACKR2—Crohn's disease	0.00512	0.0101	CbGpPWpGaD
Dextroamphetamine—Tension—Mesalazine—Crohn's disease	0.0051	0.011	CcSEcCtD
Dextroamphetamine—Nervousness—Mesalazine—Crohn's disease	0.00505	0.0109	CcSEcCtD
Dextroamphetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A1—Crohn's disease	0.00504	0.00992	CbGpPWpGaD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—PTGER4—Crohn's disease	0.00502	0.00989	CbGpPWpGaD
Dextroamphetamine—Vomiting—Mercaptopurine—Crohn's disease	0.00497	0.0108	CcSEcCtD
Dextroamphetamine—Injury—Prednisone—Crohn's disease	0.00497	0.0108	CcSEcCtD
Dextroamphetamine—Rash—Mercaptopurine—Crohn's disease	0.00493	0.0107	CcSEcCtD
Dextroamphetamine—Dermatitis—Mercaptopurine—Crohn's disease	0.00492	0.0107	CcSEcCtD
Dextroamphetamine—Tremor—Mesalazine—Crohn's disease	0.00487	0.0105	CcSEcCtD
Dextroamphetamine—TAAR1—Signaling by GPCR—MLN—Crohn's disease	0.00486	0.00956	CbGpPWpGaD
Dextroamphetamine—Angioedema—Mesalazine—Crohn's disease	0.00475	0.0103	CcSEcCtD
Dextroamphetamine—ADRA1B—G alpha (q) signalling events—MLN—Crohn's disease	0.00475	0.00935	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Dopaminergic Neurogenesis—STAT3—Crohn's disease	0.0047	0.00926	CbGpPWpGaD
Dextroamphetamine—Nausea—Mercaptopurine—Crohn's disease	0.00464	0.0101	CcSEcCtD
Dextroamphetamine—Infection—Azathioprine—Crohn's disease	0.00462	0.01	CcSEcCtD
Dextroamphetamine—Palpitations—Mesalazine—Crohn's disease	0.00459	0.00995	CcSEcCtD
Dextroamphetamine—Affect lability—Prednisone—Crohn's disease	0.00449	0.00974	CcSEcCtD
Dextroamphetamine—Hypertension—Mesalazine—Crohn's disease	0.00448	0.00972	CcSEcCtD
Dextroamphetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A1—Crohn's disease	0.00446	0.00879	CbGpPWpGaD
Dextroamphetamine—Psychotic disorder—Prednisone—Crohn's disease	0.00446	0.00966	CcSEcCtD
Dextroamphetamine—Chest pain—Mesalazine—Crohn's disease	0.00442	0.00959	CcSEcCtD
Dextroamphetamine—Anxiety—Mesalazine—Crohn's disease	0.00441	0.00955	CcSEcCtD
Dextroamphetamine—Irritability—Prednisone—Crohn's disease	0.00436	0.00944	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR ligand binding—CCR6—Crohn's disease	0.00434	0.00856	CbGpPWpGaD
Dextroamphetamine—Dry mouth—Mesalazine—Crohn's disease	0.00433	0.00937	CcSEcCtD
Dextroamphetamine—Mood swings—Prednisone—Crohn's disease	0.00432	0.00937	CcSEcCtD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—MLN—Crohn's disease	0.00424	0.00836	CbGpPWpGaD
Dextroamphetamine—Anaphylactic shock—Mesalazine—Crohn's disease	0.00424	0.00919	CcSEcCtD
Dextroamphetamine—ADRA1A—G alpha (q) signalling events—MLN—Crohn's disease	0.00422	0.0083	CbGpPWpGaD
Dextroamphetamine—Infection—Mesalazine—Crohn's disease	0.00421	0.00913	CcSEcCtD
Dextroamphetamine—Tachycardia—Mesalazine—Crohn's disease	0.00414	0.00897	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Mesalazine—Crohn's disease	0.0041	0.00888	CcSEcCtD
Dextroamphetamine—Anorexia—Mesalazine—Crohn's disease	0.00404	0.00876	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Azathioprine—Crohn's disease	0.00402	0.00871	CcSEcCtD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—ACKR2—Crohn's disease	0.00387	0.00762	CbGpPWpGaD
Dextroamphetamine—SLC18A2—SLC-mediated transmembrane transport—GCKR—Crohn's disease	0.00385	0.00758	CbGpPWpGaD
Dextroamphetamine—Insomnia—Mesalazine—Crohn's disease	0.00383	0.00831	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR ligand binding—PTGER4—Crohn's disease	0.00382	0.00753	CbGpPWpGaD
Dextroamphetamine—Gastrointestinal pain—Azathioprine—Crohn's disease	0.00381	0.00825	CcSEcCtD
Dextroamphetamine—Dyspnoea—Mesalazine—Crohn's disease	0.00378	0.00819	CcSEcCtD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—MLN—Crohn's disease	0.00377	0.00742	CbGpPWpGaD
Dextroamphetamine—Somnolence—Mesalazine—Crohn's disease	0.00377	0.00817	CcSEcCtD
Dextroamphetamine—Dyspepsia—Mesalazine—Crohn's disease	0.00373	0.00809	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR downstream signaling—CCR9—Crohn's disease	0.00371	0.0073	CbGpPWpGaD
Dextroamphetamine—Decreased appetite—Mesalazine—Crohn's disease	0.00369	0.00799	CcSEcCtD
Dextroamphetamine—Abdominal pain—Azathioprine—Crohn's disease	0.00368	0.00797	CcSEcCtD
Dextroamphetamine—Body temperature increased—Azathioprine—Crohn's disease	0.00368	0.00797	CcSEcCtD
Dextroamphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC22A4—Crohn's disease	0.00367	0.00724	CbGpPWpGaD
Dextroamphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC22A5—Crohn's disease	0.00367	0.00724	CbGpPWpGaD
Dextroamphetamine—Gastrointestinal disorder—Mesalazine—Crohn's disease	0.00366	0.00793	CcSEcCtD
Dextroamphetamine—Fatigue—Mesalazine—Crohn's disease	0.00366	0.00792	CcSEcCtD
Dextroamphetamine—Erectile dysfunction—Prednisone—Crohn's disease	0.00363	0.00787	CcSEcCtD
Dextroamphetamine—Constipation—Mesalazine—Crohn's disease	0.00363	0.00786	CcSEcCtD
Dextroamphetamine—SLC6A2—Monoamine Transport—IL1B—Crohn's disease	0.00358	0.00706	CbGpPWpGaD
Dextroamphetamine—Weight decreased—Prednisone—Crohn's disease	0.00357	0.00773	CcSEcCtD
Dextroamphetamine—Depression—Prednisone—Crohn's disease	0.00351	0.0076	CcSEcCtD
Dextroamphetamine—Acute coronary syndrome—Prednisone—Crohn's disease	0.00347	0.00751	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Mesalazine—Crohn's disease	0.00347	0.00751	CcSEcCtD
Dextroamphetamine—Myocardial infarction—Prednisone—Crohn's disease	0.00345	0.00747	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR downstream signaling—GPR65—Crohn's disease	0.00345	0.00679	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—ACKR2—Crohn's disease	0.00344	0.00677	CbGpPWpGaD
Dextroamphetamine—Hypersensitivity—Azathioprine—Crohn's disease	0.00343	0.00743	CcSEcCtD
Dextroamphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC11A1—Crohn's disease	0.0034	0.0067	CbGpPWpGaD
Dextroamphetamine—Urticaria—Mesalazine—Crohn's disease	0.00337	0.0073	CcSEcCtD
Dextroamphetamine—TAAR1—Signaling by GPCR—CCR9—Crohn's disease	0.00337	0.00663	CbGpPWpGaD
Dextroamphetamine—Abdominal pain—Mesalazine—Crohn's disease	0.00335	0.00726	CcSEcCtD
Dextroamphetamine—Body temperature increased—Mesalazine—Crohn's disease	0.00335	0.00726	CcSEcCtD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ACKR2—Crohn's disease	0.00332	0.00653	CbGpPWpGaD
Dextroamphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC22A5—Crohn's disease	0.00326	0.00641	CbGpPWpGaD
Dextroamphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC22A4—Crohn's disease	0.00326	0.00641	CbGpPWpGaD
Dextroamphetamine—Diarrhoea—Azathioprine—Crohn's disease	0.00318	0.0069	CcSEcCtD
Dextroamphetamine—SLC6A3—Monoamine Transport—IL1B—Crohn's disease	0.00317	0.00625	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—MLN—Crohn's disease	0.00314	0.00619	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—GPR65—Crohn's disease	0.00313	0.00616	CbGpPWpGaD
Dextroamphetamine—Hypersensitivity—Mesalazine—Crohn's disease	0.00312	0.00677	CcSEcCtD
Dextroamphetamine—Dizziness—Azathioprine—Crohn's disease	0.00308	0.00667	CcSEcCtD
Dextroamphetamine—ADRA1B—G alpha (q) signalling events—GPR65—Crohn's disease	0.00306	0.00602	CbGpPWpGaD
Dextroamphetamine—Asthenia—Mesalazine—Crohn's disease	0.00304	0.00659	CcSEcCtD
Dextroamphetamine—Nateglinide—ALB—Crohn's disease	0.00304	0.0983	CrCbGaD
Dextroamphetamine—TAAR1—Signaling Pathways—ACKR2—Crohn's disease	0.00303	0.00596	CbGpPWpGaD
Dextroamphetamine—Vomiting—Azathioprine—Crohn's disease	0.00296	0.00641	CcSEcCtD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—ACKR2—Crohn's disease	0.00294	0.0058	CbGpPWpGaD
Dextroamphetamine—Rash—Azathioprine—Crohn's disease	0.00293	0.00636	CcSEcCtD
Dextroamphetamine—Dermatitis—Azathioprine—Crohn's disease	0.00293	0.00635	CcSEcCtD
Dextroamphetamine—Headache—Azathioprine—Crohn's disease	0.00292	0.00632	CcSEcCtD
Dextroamphetamine—Diarrhoea—Mesalazine—Crohn's disease	0.0029	0.00629	CcSEcCtD
Dextroamphetamine—TAAR1—Signaling Pathways—MLN—Crohn's disease	0.00287	0.00565	CbGpPWpGaD
Dextroamphetamine—Dizziness—Mesalazine—Crohn's disease	0.0028	0.00608	CcSEcCtD
Dextroamphetamine—SLC6A3—Dopaminergic Neurogenesis—STAT3—Crohn's disease	0.0028	0.00552	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—MLN—Crohn's disease	0.00279	0.0055	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—SLC22A4—Crohn's disease	0.00277	0.00546	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—SLC22A5—Crohn's disease	0.00277	0.00546	CbGpPWpGaD
Dextroamphetamine—Nausea—Azathioprine—Crohn's disease	0.00276	0.00599	CcSEcCtD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—GPR65—Crohn's disease	0.00274	0.00539	CbGpPWpGaD
Dextroamphetamine—ADRA1A—G alpha (q) signalling events—GPR65—Crohn's disease	0.00272	0.00535	CbGpPWpGaD
Dextroamphetamine—Vomiting—Mesalazine—Crohn's disease	0.0027	0.00584	CcSEcCtD
Dextroamphetamine—Rash—Mesalazine—Crohn's disease	0.00267	0.00579	CcSEcCtD
Dextroamphetamine—Dermatitis—Mesalazine—Crohn's disease	0.00267	0.00579	CcSEcCtD
Dextroamphetamine—Headache—Mesalazine—Crohn's disease	0.00266	0.00576	CcSEcCtD
Dextroamphetamine—TAAR1—Signaling Pathways—TAGAP—Crohn's disease	0.00262	0.00517	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Monoamine Transport—TNF—Crohn's disease	0.0026	0.00512	CbGpPWpGaD
Dextroamphetamine—SLC6A2—SLC-mediated transmembrane transport—GCKR—Crohn's disease	0.00259	0.0051	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—CCR9—Crohn's disease	0.00254	0.00501	CbGpPWpGaD
Dextroamphetamine—Agitation—Prednisone—Crohn's disease	0.00253	0.00547	CcSEcCtD
Dextroamphetamine—ADRA1B—GPCR ligand binding—ACKR2—Crohn's disease	0.00252	0.00497	CbGpPWpGaD
Dextroamphetamine—Nausea—Mesalazine—Crohn's disease	0.00252	0.00546	CcSEcCtD
Dextroamphetamine—Angioedema—Prednisone—Crohn's disease	0.00251	0.00544	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR downstream signaling—CCR6—Crohn's disease	0.00245	0.00483	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—GPR65—Crohn's disease	0.00243	0.00478	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—MLN—Crohn's disease	0.00239	0.00471	CbGpPWpGaD
Dextroamphetamine—Convulsion—Prednisone—Crohn's disease	0.00238	0.00516	CcSEcCtD
Dextroamphetamine—Hypertension—Prednisone—Crohn's disease	0.00237	0.00514	CcSEcCtD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—GPR65—Crohn's disease	0.00236	0.00466	CbGpPWpGaD
Dextroamphetamine—Anxiety—Prednisone—Crohn's disease	0.00233	0.00505	CcSEcCtD
Dextroamphetamine—SLC6A3—Monoamine Transport—TNF—Crohn's disease	0.0023	0.00454	CbGpPWpGaD
Dextroamphetamine—SLC6A3—SLC-mediated transmembrane transport—GCKR—Crohn's disease	0.00229	0.00452	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—RSPO3—Crohn's disease	0.00229	0.00452	CbGpPWpGaD
Dextroamphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC11A1—Crohn's disease	0.00229	0.00451	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—CCR9—Crohn's disease	0.00226	0.00445	CbGpPWpGaD
Dextroamphetamine—Anaphylactic shock—Prednisone—Crohn's disease	0.00224	0.00486	CcSEcCtD
Dextroamphetamine—ADRA1A—GPCR ligand binding—ACKR2—Crohn's disease	0.00224	0.00442	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—CCR6—Crohn's disease	0.00223	0.00439	CbGpPWpGaD
Dextroamphetamine—Infection—Prednisone—Crohn's disease	0.00223	0.00483	CcSEcCtD
Dextroamphetamine—Tachycardia—Prednisone—Crohn's disease	0.00219	0.00475	CcSEcCtD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCR9—Crohn's disease	0.00218	0.00429	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—SEL1L—Crohn's disease	0.00217	0.00428	CbGpPWpGaD
Dextroamphetamine—Hyperhidrosis—Prednisone—Crohn's disease	0.00217	0.0047	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR downstream signaling—PTGER4—Crohn's disease	0.00216	0.00426	CbGpPWpGaD
Dextroamphetamine—Anorexia—Prednisone—Crohn's disease	0.00214	0.00463	CcSEcCtD
Dextroamphetamine—ADRA1A—GPCR ligand binding—MLN—Crohn's disease	0.00213	0.00419	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—GPR65—Crohn's disease	0.0021	0.00414	CbGpPWpGaD
Dextroamphetamine—Insomnia—Prednisone—Crohn's disease	0.00203	0.0044	CcSEcCtD
Dextroamphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC11A1—Crohn's disease	0.00203	0.00399	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—GPR65—Crohn's disease	0.00203	0.00399	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CCR9—Crohn's disease	0.00199	0.00392	CbGpPWpGaD
Dextroamphetamine—Dyspepsia—Prednisone—Crohn's disease	0.00197	0.00428	CcSEcCtD
Dextroamphetamine—TAAR1—Signaling by GPCR—PTGER4—Crohn's disease	0.00196	0.00387	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—GCKR—Crohn's disease	0.00196	0.00385	CbGpPWpGaD
Dextroamphetamine—Decreased appetite—Prednisone—Crohn's disease	0.00195	0.00423	CcSEcCtD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CCR9—Crohn's disease	0.00193	0.00381	CbGpPWpGaD
Dextroamphetamine—Fatigue—Prednisone—Crohn's disease	0.00193	0.00419	CcSEcCtD
Dextroamphetamine—Constipation—Prednisone—Crohn's disease	0.00192	0.00416	CcSEcCtD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC22A5—Crohn's disease	0.00187	0.00368	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC22A4—Crohn's disease	0.00187	0.00368	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—GPR65—Crohn's disease	0.00185	0.00364	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—IL3—Crohn's disease	0.00184	0.00363	CbGpPWpGaD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	0.00184	0.00362	CbGpPWpGaD
Dextroamphetamine—Gastrointestinal pain—Prednisone—Crohn's disease	0.00183	0.00398	CcSEcCtD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—GPR65—Crohn's disease	0.0018	0.00354	CbGpPWpGaD
Dextroamphetamine—Urticaria—Prednisone—Crohn's disease	0.00178	0.00386	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR downstream signaling—RASGRP1—Crohn's disease	0.00178	0.00351	CbGpPWpGaD
Dextroamphetamine—Abdominal pain—Prednisone—Crohn's disease	0.00177	0.00384	CcSEcCtD
Dextroamphetamine—Body temperature increased—Prednisone—Crohn's disease	0.00177	0.00384	CcSEcCtD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	0.00173	0.0034	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—CCR6—Crohn's disease	0.00168	0.00332	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—IL3—Crohn's disease	0.00167	0.00329	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—CCR9—Crohn's disease	0.00166	0.00327	CbGpPWpGaD
Dextroamphetamine—ADRA1B—LPA receptor mediated events—CXCL8—Crohn's disease	0.00166	0.00326	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC22A5—Crohn's disease	0.00165	0.00326	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC22A4—Crohn's disease	0.00165	0.00326	CbGpPWpGaD
Dextroamphetamine—Hypersensitivity—Prednisone—Crohn's disease	0.00165	0.00358	CcSEcCtD
Dextroamphetamine—TAAR1—Signaling by GPCR—RASGRP1—Crohn's disease	0.00162	0.00318	CbGpPWpGaD
Dextroamphetamine—Asthenia—Prednisone—Crohn's disease	0.00161	0.00349	CcSEcCtD
Dextroamphetamine—ADRA1B—G alpha (q) signalling events—RASGRP1—Crohn's disease	0.00158	0.00311	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—GPR65—Crohn's disease	0.00154	0.00304	CbGpPWpGaD
Dextroamphetamine—Diarrhoea—Prednisone—Crohn's disease	0.00153	0.00333	CcSEcCtD
Dextroamphetamine—CYP2D6—Metapathway biotransformation—GPX4—Crohn's disease	0.00153	0.00301	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—CCR6—Crohn's disease	0.0015	0.00295	CbGpPWpGaD
Dextroamphetamine—Dizziness—Prednisone—Crohn's disease	0.00148	0.00322	CcSEcCtD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—PTGER4—Crohn's disease	0.00148	0.00292	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—CCR9—Crohn's disease	0.00147	0.0029	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCR6—Crohn's disease	0.00144	0.00284	CbGpPWpGaD
Dextroamphetamine—Vomiting—Prednisone—Crohn's disease	0.00143	0.00309	CcSEcCtD
Dextroamphetamine—Rash—Prednisone—Crohn's disease	0.00141	0.00307	CcSEcCtD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—RASGRP1—Crohn's disease	0.00141	0.00278	CbGpPWpGaD
Dextroamphetamine—Dermatitis—Prednisone—Crohn's disease	0.00141	0.00306	CcSEcCtD
Dextroamphetamine—Headache—Prednisone—Crohn's disease	0.00141	0.00305	CcSEcCtD
Dextroamphetamine—ADRA1A—G alpha (q) signalling events—RASGRP1—Crohn's disease	0.0014	0.00276	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—CXCL8—Crohn's disease	0.0014	0.00276	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—GPR65—Crohn's disease	0.00137	0.0027	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—MLN—Crohn's disease	0.00135	0.00266	CbGpPWpGaD
Dextroamphetamine—Nausea—Prednisone—Crohn's disease	0.00133	0.00289	CcSEcCtD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—PTGER4—Crohn's disease	0.00132	0.00259	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CCR6—Crohn's disease	0.00132	0.00259	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—GCKR—Crohn's disease	0.00132	0.00259	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—ACKR2—Crohn's disease	0.0013	0.00255	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—IL2RA—Crohn's disease	0.00129	0.00254	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CCR6—Crohn's disease	0.00128	0.00252	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—PTGER4—Crohn's disease	0.00127	0.0025	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—RASGRP1—Crohn's disease	0.00126	0.00247	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—MLN—Crohn's disease	0.00123	0.00242	CbGpPWpGaD
Dextroamphetamine—SLC18A2—SLC-mediated transmembrane transport—ALB—Crohn's disease	0.00122	0.00241	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—MLN—Crohn's disease	0.0012	0.00237	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—RBX1—Crohn's disease	0.00119	0.00235	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—IL2RA—Crohn's disease	0.00117	0.00231	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—GCKR—Crohn's disease	0.00117	0.0023	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	0.00116	0.00229	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—PTGER4—Crohn's disease	0.00116	0.00228	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—ACKR2—Crohn's disease	0.00115	0.00227	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—PTGER4—Crohn's disease	0.00113	0.00222	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—CCR6—Crohn's disease	0.0011	0.00216	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—MLN—Crohn's disease	0.00109	0.00215	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—UBE2D1—Crohn's disease	0.00104	0.00206	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	0.00103	0.00203	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—RIPK2—Crohn's disease	0.00101	0.00199	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—IL3—Crohn's disease	0.000988	0.00194	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—CCR6—Crohn's disease	0.000976	0.00192	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—PTGER4—Crohn's disease	0.000967	0.00191	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—RASGRP1—Crohn's disease	0.000955	0.00188	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—CCR9—Crohn's disease	0.000937	0.00185	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—GPR65—Crohn's disease	0.000872	0.00172	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—JAK2—Crohn's disease	0.000867	0.00171	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—SOCS1—Crohn's disease	0.000865	0.0017	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—PTGER4—Crohn's disease	0.000859	0.00169	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CCR9—Crohn's disease	0.000851	0.00168	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—CCR9—Crohn's disease	0.000833	0.00164	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—TYK2—Crohn's disease	0.000825	0.00162	CbGpPWpGaD
Dextroamphetamine—SLC6A2—SLC-mediated transmembrane transport—ALB—Crohn's disease	0.000824	0.00162	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—GPR65—Crohn's disease	0.000791	0.00156	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—CXCL8—Crohn's disease	0.000791	0.00156	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—JAK2—Crohn's disease	0.000787	0.00155	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—GPR65—Crohn's disease	0.000774	0.00152	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ACKR2—Crohn's disease	0.000765	0.00151	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CCR9—Crohn's disease	0.000756	0.00149	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—SMAD3—Crohn's disease	0.000747	0.00147	CbGpPWpGaD
Dextroamphetamine—SLC6A3—SLC-mediated transmembrane transport—ALB—Crohn's disease	0.00073	0.00144	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MLN—Crohn's disease	0.000726	0.00143	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—Crohn's disease	0.000721	0.00142	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—CXCL8—Crohn's disease	0.000718	0.00141	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—GPR65—Crohn's disease	0.000703	0.00138	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—IL2RA—Crohn's disease	0.000692	0.00136	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—JAK2—Crohn's disease	0.000688	0.00136	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ACKR2—Crohn's disease	0.00068	0.00134	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TAGAP—Crohn's disease	0.000664	0.00131	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MLN—Crohn's disease	0.000644	0.00127	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—Crohn's disease	0.000641	0.00126	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—ALB—Crohn's disease	0.000622	0.00123	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—CCR6—Crohn's disease	0.000621	0.00122	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—JAK2—Crohn's disease	0.000611	0.0012	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TAGAP—Crohn's disease	0.000589	0.00116	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—RSPO3—Crohn's disease	0.00058	0.00114	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CCR6—Crohn's disease	0.000564	0.00111	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—CCR6—Crohn's disease	0.000552	0.00109	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—SEL1L—Crohn's disease	0.00055	0.00108	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—PTGER4—Crohn's disease	0.000547	0.00108	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—RSPO3—Crohn's disease	0.000515	0.00101	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CCR9—Crohn's disease	0.000503	0.00099	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CCR6—Crohn's disease	0.000501	0.000987	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PTGER4—Crohn's disease	0.000496	0.000978	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—SEL1L—Crohn's disease	0.000488	0.000962	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—TYK2—Crohn's disease	0.000487	0.00096	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—PTGER4—Crohn's disease	0.000486	0.000956	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—GPR65—Crohn's disease	0.000468	0.000921	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—IL3—Crohn's disease	0.000466	0.000917	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	0.000465	0.000916	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—JAK2—Crohn's disease	0.000465	0.000916	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—RASGRP1—Crohn's disease	0.00045	0.000887	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CCR9—Crohn's disease	0.000447	0.00088	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PTGER4—Crohn's disease	0.000441	0.000869	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PLA2G4F—Crohn's disease	0.000427	0.000841	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CXCL8—Crohn's disease	0.000424	0.000836	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—IL3—Crohn's disease	0.000423	0.000833	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—ALB—Crohn's disease	0.000419	0.000825	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—GPR65—Crohn's disease	0.000415	0.000818	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—IL3—Crohn's disease	0.000414	0.000815	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	0.000413	0.000813	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—RASGRP1—Crohn's disease	0.000409	0.000806	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—IL6—Crohn's disease	0.000404	0.000795	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—RASGRP1—Crohn's disease	0.0004	0.000788	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—IL3—Crohn's disease	0.000376	0.00074	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—ALB—Crohn's disease	0.000371	0.00073	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—RASGRP1—Crohn's disease	0.000363	0.000716	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—MTMR3—Crohn's disease	0.000363	0.000715	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—CXCL8—Crohn's disease	0.000354	0.000697	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Crohn's disease	0.000353	0.000695	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—STAT3—Crohn's disease	0.000341	0.000672	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CCR6—Crohn's disease	0.000333	0.000656	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—IL2RA—Crohn's disease	0.000326	0.000642	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—CXCL8—Crohn's disease	0.000315	0.000619	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Crohn's disease	0.000313	0.000617	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—RBX1—Crohn's disease	0.000301	0.000593	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—IL2RA—Crohn's disease	0.000296	0.000583	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CCR6—Crohn's disease	0.000296	0.000583	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PTGER4—Crohn's disease	0.000293	0.000578	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—IL2RA—Crohn's disease	0.00029	0.000571	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—FADS1—Crohn's disease	0.000283	0.000557	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—RBX1—Crohn's disease	0.000268	0.000527	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GPX4—Crohn's disease	0.000265	0.000521	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—UBE2D1—Crohn's disease	0.000264	0.00052	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—IL2RA—Crohn's disease	0.000263	0.000518	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PTGER4—Crohn's disease	0.000261	0.000513	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—RIPK2—Crohn's disease	0.000256	0.000505	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GCKR—Crohn's disease	0.000256	0.000504	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IL3—Crohn's disease	0.00025	0.000492	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—RASGRP1—Crohn's disease	0.000242	0.000476	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—IL6—Crohn's disease	0.000238	0.000469	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—UBE2D1—Crohn's disease	0.000235	0.000462	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—RIPK2—Crohn's disease	0.000228	0.000448	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IL3—Crohn's disease	0.000222	0.000437	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—JAK2—Crohn's disease	0.000219	0.000432	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—SOCS1—Crohn's disease	0.000219	0.000431	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—RASGRP1—Crohn's disease	0.000215	0.000423	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—TYK2—Crohn's disease	0.000209	0.000411	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—CXCL8—Crohn's disease	0.0002	0.000394	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—JAK2—Crohn's disease	0.000199	0.000392	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—JAK2—Crohn's disease	0.000195	0.000384	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—SOCS1—Crohn's disease	0.000194	0.000383	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—SMAD3—Crohn's disease	0.000189	0.000372	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—TYK2—Crohn's disease	0.000185	0.000365	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CXCL8—Crohn's disease	0.000182	0.000358	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—CXCL8—Crohn's disease	0.000178	0.00035	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—JAK2—Crohn's disease	0.000177	0.000348	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IL2RA—Crohn's disease	0.000175	0.000345	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—SMAD3—Crohn's disease	0.000168	0.000331	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CXCL8—Crohn's disease	0.000161	0.000318	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IL2RA—Crohn's disease	0.000155	0.000306	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TYK2—Crohn's disease	0.000123	0.000243	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—JAK2—Crohn's disease	0.000118	0.000232	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TYK2—Crohn's disease	0.00011	0.000216	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CXCL8—Crohn's disease	0.000107	0.000211	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—JAK2—Crohn's disease	0.000104	0.000206	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—IL6—Crohn's disease	0.000102	0.000201	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CXCL8—Crohn's disease	9.54e-05	0.000188	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—IL6—Crohn's disease	9.07e-05	0.000179	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—STAT3—Crohn's disease	8.63e-05	0.00017	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ALB—Crohn's disease	8.14e-05	0.00016	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—STAT3—Crohn's disease	7.67e-05	0.000151	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PTGS2—Crohn's disease	7.12e-05	0.00014	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IL6—Crohn's disease	6.03e-05	0.000119	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IL6—Crohn's disease	5.36e-05	0.000105	CbGpPWpGaD
